Ultime notizie per Ventas (NYSE:VTR) Azioni

Ventas

Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.

Ventas Inc

VETROPACK HLDF ST PRX A by Vetropack Holding SA

Vitrolife AB

VECTRON SYSTEMS AG NEW by Vectron Systems AG New

Vectron Systems AG

Viatris Inc

VECTOR INC TOKYO by Vector Inc.

Vitru Ltd

In the current market session, Ventas Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) share price is at $68.76, after a 1.16% spike. Moreover, over the past month, the stock fell by 0.61%, but in the past year, spiked by 60.43%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1743195619_0.png" alt="Past Year Chart" />

<h3>Ventas P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 107.39 in the Helath Care REITs industry, Ventas Inc. has a higher P/E ratio of 357.74. Shareholders might be inclined to think that Ventas Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743195619_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

Price Over Earnings Overview: Ventas

Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) has outperformed the market over the past 5 years by 2.99% on an annualized basis producing an average annual return of 21.38%. Currently, Ventas has a market capitalization of $29.60 billion. 
Buying $100 In VTR: If an investor had bought $100 of VTR stock 5 years ago, it would be worth $294.39 today based on a price of $67.71 for VTR at the time of writing.
<h3>Ventas's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742512511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Ventas 5 Years Ago Would Be Worth This Much Today

Mizuho analyst Vikram Malhorta maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and raises the price target from $68 to $75.

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Ventas, Raises Price Target to $75

Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) has outperformed the market over the past 5 years by 5.99% on an annualized basis producing an average annual return of 25.76%. Currently, Ventas has a market capitalization of $29.24 billion. 
Buying $100 In VTR: If an investor had bought $100 of VTR stock 5 years ago, it would be worth $340.44 today based on a price of $66.90 for VTR at the time of writing.
<h3>Ventas's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742226308_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Ventas Stock In The Last 5 Years

Morgan Stanley analyst Richard Hill maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Equal-Weight and raises the price target from $65 to $70.

Morgan Stanley Maintains Equal-Weight on Ventas, Raises Price Target to $70

8 analysts have expressed a variety of opinions on Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $71.75, with a high estimate of $78.00 and a low estimate of $65.00. This current average reflects an increase of 4.36% from the previous average price target of $68.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1741633362_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Ventas among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$77.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$72.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$74.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$69.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ventas. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Ventas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ventas's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ventas analyst ratings.</a>
<h2>Discovering Ventas: A Closer Look</h2>
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Ventas's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Ventas showcased positive performance, achieving a revenue growth rate of 10.53% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Ventas's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 4.42%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ventas's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.55%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.22%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Ventas's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.28.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Ventas: Insights From 8 Financial Analysts

Wells Fargo analyst John Kilichowski maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Overweight and raises the price target from $72 to $77.

Wells Fargo Maintains Overweight on Ventas, Raises Price Target to $77

JP Morgan analyst Michael Mueller maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Neutral and raises the price target from $71 to $73.

JP Morgan Maintains Neutral on Ventas, Raises Price Target to $73

WIIM

CBRE

EQIX

WELL

WHLR

Shares of REIT and utility stocks are trading lower amid overall market weakness. Rising Treasury yields may be driving a rotation out of income-paying sectors.

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has fallen 14.65% since its last report. The company recently reported that it has 10.96 million shares sold short, which is 3.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741113038_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 7.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Ventas Gaining or Losing Market Support?

RBC Capital analyst Michael Carroll maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and raises the price target from $70 to $74.

RBC Capital Maintains Outperform on Ventas, Raises Price Target to $74

In the last three months, 5 analysts have published ratings on Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $69.2, a high estimate of $78.00, and a low estimate of $65.00. Surpassing the previous average price target of $67.80, the current average has increased by 2.06%.
<img src="https://www.benzinga.com/files/images/story/2025/1739556051_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Ventas among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$69.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$71.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ventas. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Ventas's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ventas's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ventas analyst ratings.</a>
<h2>Get to Know Ventas Better</h2>
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Ventas: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Ventas displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.52%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ventas's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.2%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.08%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.42, Ventas adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Ventas: What You Need To Know

Wedbush analyst Richard Anderson maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Outperform and raises the price target from $69 to $78.

Wedbush Maintains Outperform on Ventas, Raises Price Target to $78

General

Ventas shares are trading higher after the company reported better-than-expected Q4 financial results.

Guidance

Ventas Sees FY25 Normalized FFO Per Share Midpoint $3.41

Earnings

Earnings Beats

Ventas Q4 2024 FFO $0.81 Beats $0.80 Estimate, Sales $1.287B Beat $1.262B Estimate

ACRE

AEIS

AEMD

ALCO

ALKS

AMWL

ASND

ASPN

ATRC

AVXL

AYTU

BIIB

BROS

BXMT

CAMT

CGNX

CHEF

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PEGA

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

Ratings for Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $67.0, a high estimate of $69.00, and a low estimate of $65.00. This current average has decreased by 0.74% from the previous average price target of $67.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1738004441_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Ventas by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$69.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$71.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ventas. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ventas compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Ventas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ventas's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ventas analyst ratings.</a>
<h2>All You Need to Know About Ventas</h2>
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
<h3>Financial Insights: Ventas</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Ventas displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.52%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Ventas's net margin excels beyond industry benchmarks, reaching 1.56%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ventas's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.2%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ventas's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.08% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Ventas's debt-to-equity ratio is below the industry average at 1.42, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Ventas Stock

Scotiabank analyst Nicholas Yulico maintains Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) with a Sector Perform and raises the price target from $68 to $69.

Scotiabank Maintains Sector Perform on Ventas, Raises Price Target to $69

Ventas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) short percent of float has fallen 48.99% since its last report. The company recently reported that it has 10.98 million shares sold short, which is 3.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.03 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ventas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737658813_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ventas has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ventas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ventas's peer group average for short interest as a percentage of float is 7.61%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Ventas?

Press Releases

Ventas Earns Nareit 2024 Healthcare "Leader in the Light" Award

Ventas Comments on Master Lease with Brookdale Senior Living

Ventas Declares Fourth Quarter 2024 Dividend of $0.45 Per Common Share

Ventas Reaches Mutually Beneficial Agreements with Brookdale Senior Living

Ventas Announces Fourth Quarter 2024 Earnings Release Date and Conference Call

Ventas Announces Tax Treatment Of 2024 Distributions

Ventas Reports 2024 Full Year Results, Provides 2025 Outlook and Increases Dividend

Ventas to Participate in Investor Meetings at Citi 2025 Global Property CEO Conference

Ventas Announces First Quarter 2025 Earnings Release Date and Conference Call

Land & Buildings Sends Letter to National Health Investors Stockholders and Files Definitive Proxy Materials Detailing Urgent Need for Boardroom Change

Comments

Ventas

Notizie

Ultime notizie per Ventas (NYSE:VTR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO